Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-348 in Healthy Volunteers
NCT ID: NCT04272502
Last Updated: 2020-02-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
15 participants
INTERVENTIONAL
2019-06-04
2019-08-26
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(3) 80/20/10mg
NCT05245084
Clinical Trial to Evaluate the Tolerability and the Pharmacokinetics of CKD-348
NCT05549401
A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-348(5)
NCT05749861
Clinical Study to Investigate the PK Profiles and Safety of CKD-385 in Healthy Volunteers Under Fed Conditions
NCT04906785
Study to Evaluate the Safety and Pharmacokinetics of CKD-349 in Healthy Adult Volunteers
NCT05089279
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Sequence A
CKD-828, D326, D337, CKD-F1, CKD-F2
CKD-348 F1, CKD-348 F2, CKD-828, D326, D337
Each arm has a different order for taking IP
Sequence B
CKD-828, D326, D337, CKD-F1, CKD-F2
CKD-348 F1, CKD-348 F2, CKD-828, D326, D337
Each arm has a different order for taking IP
Sequence C
CKD-828, D326, D337, CKD-F1, CKD-F2
CKD-348 F1, CKD-348 F2, CKD-828, D326, D337
Each arm has a different order for taking IP
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CKD-348 F1, CKD-348 F2, CKD-828, D326, D337
Each arm has a different order for taking IP
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Health Volunteers
3. Subject who agreeds to participate in this clinical trial voluntarily
Exclusion Criteria
19 Years
45 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Seoul National University Bundang Hospital
OTHER
Chong Kun Dang Pharmaceutical
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Seoul National University Bundang Hospital
Gyeonggi-do, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A86_02BE1902P
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.